US09627Y1091 - Common Stock - After market: 45.65 0 (0%)
NASDAQ:BPMC (2/3/2023, 7:28:23 PM)-3.41 (-6.95%)
|GICS Sector||Health Care|
|Earnings (Last)||11-01 2022-11-01/bmo||Earnings (Next)||02-14 2023-02-14/amc|
|Ins Owners||1.29%||Inst Owners||104.52%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Blueprint Medicines Corp. is a precision therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 602 full-time employees. The company went IPO on 2015-04-30. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). The company is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The firm is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.
BLUEPRINT MEDICINES CORP
45 Sidney Street
Cambridge MASSACHUSETTS 02139
CEO: Jeffrey W. Albers
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of...
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's...
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors. Dr. Tsai, who was...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...
Needham issued a Buy rating on Cogent Biosciences (COGT) on Wednesday, citing better prospects for its systemic mastocytosis candidate bezuclastinib. Read the full story here.
Needham launched its coverage on Blueprint Medicines Corporation (BPMC) on Wednesday with a Buy recommendation, citing sales potential of its cancer medication Ayvakit. Read full story here.
Here you can normally see the latest stock twits on BPMC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.